文献速递儿科影像技术与安全PETCT

治疗前18F-FDG PET/CT对儿童神经母细胞瘤的预后意义

Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma.
PubMed 文献 · Pediatr Radiol · 2021-02-25

本回顾性研究纳入55例新诊断神经母细胞瘤患儿,评估治疗前18F-FDG PET/CT代谢参数与预后的关系。SUVmax、肿瘤体积和总病灶糖酵解在MYCN扩增肿瘤及较高INRG分期中更高。校正年龄后SUVmax与SUVmean与总生存相关,但控制MYCN状态、分期或治疗危险分层后无独立预后价值。

要点

  • SUVmax、肿瘤体积和总病灶糖酵解在MYCN扩增及高INRG分期肿瘤中更高。
  • SUVmax阈值4.77可最佳预测总生存,但非独立于其他预后标志物。
  • 控制MYCN状态、分期或治疗危险分层后,无PET参数独立显著相关。

诊断标准与关键数值

  • SUVmax、肿瘤体积和总病灶糖酵解在MYCN扩增肿瘤中更高(P=0.012、P<0.0001、P<0.0001)。
  • SUVmax、肿瘤体积和总病灶糖酵解在较高INRG分期中更高(P=0.0008、P=0.0017、P=0.0017)。
  • 校正年龄后,肿瘤SUVmax(P=0.028)和SUVmean(P=0.045)与总生存相关。
  • SUVmax阈值4.77(P=0.028)最佳预测总生存,中位总生存为2604天(SUVmax>4.77)对比>2957天(SUVmax≤4.77)。
  • 控制MYCN状态、分期或治疗危险分层后,无PET参数独立显著与总生存或无事件生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: 18F-2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) shows tumor activity in most neuroblastomas, but the role of 18F-FDG PET/CT in neuroblastoma remains to be defined.

OBJECTIVE: This study explored the prognostic significance of 18F-FDG PET in newly diagnosed neuroblastic tumors.

MATERIALS AND METHODS: This retrospective study reviewed all 18F-FDG PET/CT examinations performed for a new diagnosis of suspected neuroblastoma. MYCN amplification status, tumor recurrence and survival were abstracted from the medical record. Primary tumors were manually segmented to measure maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor volume and total lesion glycolysis. Univariate and multivariable analyses using Cox proportional hazards regression testing assessed the predictive performance of PET indices for event-free survival and overall survival with thresholds determined using receiver operating characteristic curve analysis.

RESULTS: Fifty-five children were included, with a median age of 2.9 years (interquartile range [IQR] 1.8-3.0 years). SUVmax, tumor volume and total lesion glycolysis were higher in MYCN-amplified tumors (P=0.012, P<0.0001, P<0.0001, respectively) and in higher International Neuroblastoma Risk Group (INRG) stages (P=0.0008, P=0.0017, P=0.0017, respectively). After adjusting for age, tumor SUVmax (P=0.028) and SUVmean (P=0.045) were associated with overall survival. An SUVmax threshold of 4.77 (P=0.028) best predicted overall survival, with median overall survival of 2,604 days (SUVmax>4.77) vs. >2,957 days (SUVmax≤4.77). No PET parameters were independently significantly associated with overall survival or event-free survival after controlling for MYCN status, stage or treatment risk stratification.

CONCLUSION: Tumor metabolic activity is higher in higher-stage MYCN-amplified neuroblastic tumors. Higher SUVmax and SUVmean were associated with worse overall survival but were not independent of other prognostic markers.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Sung AJ, Weiss BD, Sharp SE, et al. Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma. Pediatr Radiol. 2021. PMID: 33629142. doi:10.1007/s00247-021-05005-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。